Integrated Continuous Bioprocessing Platform
Integrated Continuous Bioprocessing Platform
Targeted indication
1. High cell density perfusion culture.
2. Continuous chromatography for downstream processing.
3. In extreme favor of monitoring or improving quality and quantity.
4. Higher productivity and cost-saving than the traditional fed-batch manufacturing process.
Status
Key features
- DCB has established an integrated continuous biomanufacturing system connecting the module of high cell-density perfusion culture to the continuous chromatography system; the VCD of perfusion culture is 50 ~ 80 x 106 cells/ml and produce antibody of about 2.0~3.0 g/L/day within 6 weeks.
Market
- Constant of quality and quantity.
- Higher productivity and cost-reduction
MODE OF ACTION
EXPERIMENTAL RESULTS
NA
DCB has established an integrated continuous biomanufacturing system connecting the module of high cell-density perfusion culture to the continuous chromatography system; the VCD of perfusion culture is 50 ~ 80 x 106 cells/ml and produce antibody of about 2.0~3.0 g/L/day within 6 weeks.
INTELLECTUAL PROPERTY
SELECTED PUBLICATIONS
NA
BUSINESS OPPORTUNITY
Biologics production; Adaptation to automation
CONTACT
service@biip-dcc.org